+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07015905

Evaluating REGN7508 Compared to Apixaban and Enoxaparin for Preventing Blood Clots After Elective Total Knee Replacement Surgery

Led by Regeneron Pharmaceuticals · Updated on 2026-10-08

2000

Participants Needed

47

Research Sites

11 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate an experimental drug called REGN7508 in adults undergoing elective unilateral total knee replacement surgery. The study focuses on how well REGN7508 prevents venous thromboembolism VTE and related conditions after surgery. It also investigates side effects, blood levels of the study drug, and whether the body develops antibodies against the drug, which could affect its action or cause side effects. Participants are randomly assigned to receive one of several treatments intravenous REGN7508, subcutaneous REGN7508 with intravenous placebo, oral apixaban with intravenous placebo, or subcutaneous enoxaparin with intravenous placebo. All treatments are given according to the study protocol. The primary evaluation period lasts through approximately 14 days after surgery. During the study, participants undergo monitoring for VTE events including deep vein thrombosis and pulmonary embolism, bleeding events, and adverse reactions up to about 90 days after surgery. Blood samples are taken to measure drug concentration and antibody formation. The main outcome measured is the incidence of VTE through day 12. Safety and drug activity are closely tracked throughout the study period.

CONDITIONS

Brief Title

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here